Comparing two ways to give immunotherapy for stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug (AK104) given under the skin versus in the vein, both combined with chemotherapy, for people with advanced stomach or gastroesophageal junction cancer that can't be removed by surgery and hasn't been treated yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach cancer or cancer where the stomach meets the esophagus that can't be removed by surgery or has spread to other parts of the body.
- You haven't had any previous chemotherapy or other treatments for this advanced cancer.
- You are feeling well enough to be up and about (ECOG score 0 or 1).
- You have at least one tumor that can be measured on a scan.
- Your blood counts and organ function are adequate (your doctor will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy for people with advanced stomach cancer that hasn't been treated yet. It compares this combination to chemotherapy with or without another immunotherapy drug, nivolumab.
This trial tests a new combination of immunotherapy drugs (AK129 and cadonilimab) plus chemotherapy for people with advanced stomach or GEJ cancer who have not had treatment before. The goal is to see if adding these immunotherapies helps shrink tumors or slow cancer growth better than chemotherapy alone.
This trial tests a combination of two experimental immunotherapies (AK104 and AK109) with a standard chemo drug (paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has grown after initial treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer better than chemo alone.
This Phase 1/2 study tests the safety and effectiveness of two investigational drugs (AK109 and AK104) in people with advanced stomach (or lower esophagus/GEJ) cancer. It’s for cases where the cancer did not respond to first-line treatment that included anti–PD-1/PD-L1 therapy plus chemotherapy.
This trial tests a new immunotherapy drug (SHR-1701) combined with chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal metastasis) but not to other organs like the liver or lungs. The goal is to see if this combination can help shrink or control the cancer before any surgery.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.